Regenerative Medical Solutions (RMS) continues to make strides toward its mission of curing diabetes. During a recent interview with Drew Mariani on Relevant Radio, RMS leadership team members, CEO Anthony Kolton and Scientific Founder Dr. Jon S. Odorico, discussed the company’s progress and shared exciting news: the launch of RMS’s humanized mouse study, which began just a few weeks prior. This milestone underscores RMS’s leadership in diabetes cure research and advances its work in stem cell therapy for diabetes.
Jon and Tony also took various questions from callers, including challenging questions about how their prospective diabetes cure would work for type 2 diabetes.
A Prospective Cure for Diabetes that Doesn’t Require Immunosuppression
RMS is developing a functional cure for diabetes that does not require immunosuppressive drugs; this is the main differentiator between RMS and its competitors. During the interview, Jon reminded listeners that immunosuppression is a “double edged sword”; while it prevents rejection, it is also associated with increased risk of infection, it makes it more difficult to treat some cancers, and can increase the risk of developing some cancers. Jon explained that during the pandemic, when a patient on immunosuppressive drugs got COVID-19, they were given a 20% mortality rate. This focus on eliminating immunosuppression is central to RMS’s stem cell therapy for diabetes.
A Crucial Step Forward in Diabetes Research
The humanized mouse study represents a critical milestone in RMS’s journey to validate its stem cell therapy for diabetes. This stage allows the research team to observe how human-derived insulin-producing cells (ILCs) perform within a biological system designed to model human immune responses. The results from this study will play a central role in confirming the safety and long-term functionality of RMS’s potential cure and furthering its diabetes cure research pipeline.
According to Kolton and Dr. Odorico, the biotechnology company’s goal is to create insulin-producing cells derived from induced pluripotent stem cells (iPSCs) that are both safe and immune-resistant, a groundbreaking step toward providing a functional, long-term solution for Type 1 and Type 2 diabetes. These iPSC-derived ILCs are at the core of RMS’s stem cell therapy for diabetes strategy.
Building on NIH-Funded Momentum
The new study follows RMS’s recent $1.8 million NIH grant, awarded to support its proof-of-concept work. That funding enables the biotechnology company to continue refining its process for creating unlimited, ethically sourced insulin-producing cells, offering hope to millions of people living with diabetes. This grantfueled progress strengthens RMS’s position at the forefront of diabetes cure research.
The Collaborative Vision
Behind RMS Dr. Odorico, who has dedicated over two decades to pancreatic stem cell research at the University of Wisconsin–Madison, emphasized the importance of collaboration in RMS’s success. The company’s work bridges academic innovation with commercial development, helping translate regenerative medicine breakthroughs from the lab bench to patient-ready therapies, an essential pathway for impactful stem cell therapy for diabetes.
Looking Ahead: Preparing for Clinical Trials
With early data from the humanized mouse model expected in the coming months, RMS is preparing for the next phase of its research pipeline, the transition from preclinical validation to clinical readiness. The biotech company aims to demonstrate that its iPSC-derived ILCs can restore insulin production effectively and safely, without the complications that have historically limited donor-based transplants. These upcoming milestones mark meaningful momentum in RMS’s diabetes cure research and the real-world translation of its stem cell therapy for diabetes.
Contact Us
To hear the full discussion with Anthony Kolton and Dr. Jon S. Odorico, listen to the interview on YouTube. For information about investment opportunities or RMS’s ongoing research, contact us or email Tom Joyce at tjoyce@regenmedsolutions.com.